Opus Registry

US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice

Opus Registry [NCT02126943]

Description: Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.

Drug: Opsumit (macitentan)

Primary Investigator: Engel

Drug/Device Information
Observational registry to characterize the safety profile, describe clinical characteristics and outcomes of patients newly treated with Opsumit
Opsumit (macitentan) is a newly available endothelin receptor antagonist
Nonrandomized (observational registry)
Actelion